The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
Abstract
Infiltration of human melanomas with cytotoxic immune cells correlates with spontaneous type I IFN activation and a favorable prognosis. Therapeutic blockade of immune-inhibitory receptors in patients with preexisting lymphocytic infiltrates prolongs survival, but new complementary strategies are needed to activate cellular antitumor immunity in immune cell–poor melanomas. Here, we show that primary melanomas in Hgf-Cdk4R24C mice, which imitate human immune cell–poor melanomas with a poor outcome, escape IFN-induced immune surveillance and editing. Peritumoral injections of immunostimulatory RNA initiated a cytotoxic inflammatory response in the tumor microenvironment and significantly impaired tumor growth. This critically required the coordinated induction of type I IFN responses by dendritic, myeloid, natural killer, and T cells. Importantly, antibody-mediated blockade of the IFN-induced immune-inhibitory interaction between PD-L1 and PD-1 receptors further prolonged the survival. These results highlight important interconnections between type I IFNs and immune-inhibitory receptors in melanoma pathogenesis, which serve as targets for combination immunotherapies. Significance: Using a genetically engineered mouse melanoma model, we demonstrate that targeted activation of the type I IFN system with immunostimulatory RNA in combination with blockade of immune-inhibitory receptors is a rational strategy to expose immune cell–poor tumors to cellular immune surveillance. Cancer Discov; 4(6); 674–87. ©2014 AACR. This article is highlighted in the In This Issue feature, p. 621
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617
Fuertes, M. B., Kacha, A. K., Kline, J., Woo, S.-R., Kranz, D. M., Murphy, K. M., & Gajewski, T. F. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101159 · Cited by 1,192
Gitlin, L., Barchet, W., Gilfillan, S., Cella, M., Beutler, B., Flavell, R. A., Diamond, M. S., & Colonna, M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603082103 · Cited by 1,169
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., Lee, H., Arthur, C. D., White, J. M., Kalinke, U., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101158 · Cited by 1,081
Self-citationNatural selection of tumor variants in the generation of “tumor escape” phenotypes
Khong, H. T., & Restifo, N. P. (2002) · Nature Immunology · doi:10.1038/ni1102-999 · Cited by 1,058
Azimi, F., Scolyer, R. A., Rumcheva, P., Moncrieff, M., Murali, R., McCarthy, S. W., Saw, R. P., & Thompson, J. F. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.8539 · Cited by 856
Holmgaard, R. B., Zamarin, D., Munn, D. H., Wolchok, J. D., & Allison, J. P. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130066 · Cited by 634
Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation
Landsberg, J., Kohlmeyer, J., Renn, M., Bald, T., Rogava, M., Cron, M., Fatho, M., Lennerz, V., Wölfel, T., Hölzel, M., et al. (2012) · Nature · doi:10.1038/nature11538 · Cited by 632
Self-citationA critical function for type I interferons in cancer immunoediting
Dunn, G. P., Bruce, A. T., Sheehan, K. C. F., Shankaran, V., Uppaluri, R., Bui, J. D., Diamond, M. S., Koebel, C. M., Arthur, C., White, J. M., et al. (2005) · Nature Immunology · doi:10.1038/ni1213 · Cited by 605
Erdag, G., Schaefer, J. T., Smolkin, M. E., Deacon, D. H., Shea, S. M., Dengel, L. T., Patterson, J. W., & Slingluff, C. L. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3218 · Cited by 590
Expression of tumour-specific antigens underlies cancer immunoediting
DuPage, M., Mazumdar, C., Schmidt, L. M., Cheung, A. F., & Jacks, T. (2012) · Nature · doi:10.1038/nature10803 · Cited by 529
PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines
Peng, W., Liu, C., Xu, C., Lou, Y., Chen, J., Yang, Y., Yagita, H., Overwijk, W. W., Lizée, G., Radvanyi, L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1187 · Cited by 432
Bogunovic, D., O'Neill, D. W., Belitskaya-Levy, I., Vacic, V., Yu, Y.-L., Adams, S., Darvishian, F., Berman, R., Shapiro, R., Pavlick, A. C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905139106 · Cited by 384
IL-18 Induces PD-1–Dependent Immunosuppression in Cancer
Terme, M., Ullrich, E., Aymeric, L., Meinhardt, K., Desbois, M., Delahaye, N., Viaud, S., Ryffel, B., Yagita, H., Kaplanski, G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0993 · Cited by 376
Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia
Kamphuis, E., Junt, T., Waibler, Z., Forster, R., & Kalinke, U. (2006) · Blood · doi:10.1182/blood-2006-06-027599 · Cited by 306
Self-citationTaylor, R. C., Patel, A., Panageas, K. S., Busam, K. J., & Brady, M. S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.9755 · Cited by 297
Jönsson, G., Busch, C., Knappskog, S., Geisler, J., Miletic, H., Ringnér, M., Lillehaug, J. R., Borg, Å., & Lønning, P. E. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2509 · Cited by 283
Self-citationPlasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
Hölzel, M., Bovier, A., & Tüting, T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3498 · Cited by 269
Self-citationDuPage, M., Cheung, A. F., Mazumdar, C., Winslow, M. M., Bronson, R., Schmidt, L. M., Crowley, D., Chen, J., & Jacks, T. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.011 · Cited by 244
Okunishi, K., Dohi, M., Nakagome, K., Tanaka, R., Mizuno, S., Matsumoto, K., Miyazaki, J.-I., Nakamura, T., & Yamamoto, K. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.7.4745 · Cited by 240
A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells.
Qin, Z., Schwartzkopff, J., Pradera, F., Kammertoens, T., Seliger, B., Pircher, H., & Blankenstein, T. J. F. (2003) · PubMed · Cited by 235
Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors
Shime, H., Matsumoto, M., Oshiumi, H., Tanaka, S., Nakane, A., Iwakura, Y., Tahara, H., Inoue, N., & Seya, T. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113099109 · Cited by 224
Steitz, J., Brück, J., Lenz, J., Knop, J., & Tüting, T. (2001) · PubMed · Cited by 214
Self-citationBenkhoucha, M., Santiago-Raber, M.-L., Schneiter, G., Chofflon, M., Funakoshi, H., Nakamura, T., & Lalive, P. H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912437107 · Cited by 205
Akazawa, T., Ebihara, T., Okuno, M., Okuda, Y., Shingai, M., Tsujimura, K., Takahashi, T., Ikawa, M., Okabe, M., Inoue, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605978104 · Cited by 188
Mann, G. J., Pupo, G. M., Campain, A. E., Carter, C. D., Schramm, S.-J., Pianova, S., Gerega, S. K., De Silva, C., Lai, K., Wilmott, J. S., et al. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.283 · Cited by 183
Transcriptome Profiling Identifies HMGA2 as a Biomarker of Melanoma Progression and Prognosis
Raskin, L., Fullen, D. R., Giordano, T. J., Thomas, D. G., Frohm, M. L., Cha, K. B., Ahn, J., Mukherjee, B., Johnson, T. M., & Gruber, S. B. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.197 · Cited by 165
van Houdt, I. S., Sluijter, B. J. R., Moesbergen, L. M., Vos, W., de Gruijl, T. D., Molenkamp, B. G., van den Eertwegh, A. J. M., Hooijberg, E., van Leeuwen, P. A. M., Meijer, C. J. L. M., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23543 · Cited by 138
Miyake, T., Kumagai, Y., Kato, H., Guo, Z., Matsushita, K., Satoh, T., Kawagoe, T., Kumar, H., Jang, M. H., Kawai, T., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901500 · Cited by 115
Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma
Harbst, K., Staaf, J., Lauss, M., Karlsson, A., Måsbäck, A., Johansson, I., Bendahl, P.-O., Vallon-Christersson, J., Törngren, T., Ekedahl, H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0343 · Cited by 105
Self-citationType I Interferon-Associated Recruitment of Cytotoxic Lymphocytes
Wenzel, J., Bekisch, B., Uerlich, M., Haller, O., Bieber, T. R. M., & Tüting, T. (2005) · American Journal of Clinical Pathology · doi:10.1309/4ej9-kl7c-gden-vvle · Cited by 99
Self-citationDuPage, M. J. P., & Jacks, T. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.02.005 · Cited by 92
IFN-α-Expressing Tumor Cells Enhance Generation and Promote Survival of Tumor-Specific CTLs
Hiroishi, K., Tüting, T., & Lotze, M. T. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.2.567 · Cited by 77
Self-citationIntratumoral T-Cell Infiltrates and MHC Class I Expression in Patients with Stage IV Melanoma
Al‐Batran, S., Rafiyan, M., Atmaca, A., Neumann, A., Karbach, J., Bender, A., Weidmann, E., Altmannsberger, H., Knuth, A. K., & Jäger, E. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4621 · Cited by 70
Kholmanskikh, O., van Baren, N., Brasseur, F., Ottaviani, S., Vanacker, J., Arts, N., van der Bruggen, P., Coulie, P. G., & Plaen, E. D. (2010) · International Journal of Cancer · doi:10.1002/ijc.25182 · Cited by 70
Mizutani, T., Neugebauer, N., Putz, E. M., Moritz, N., Simma, O., Zebedin-Brandl, E. M., Gotthardt, D., Warsch, W., Eckelhart, E., Kantner, H.-P., et al. (2012) · OncoImmunology · doi:10.4161/onci.21284 · Cited by 67
Self-citationInnate immune sensing of cancer: clues from an identified role for type I IFNs
Gajewski, T. F., Fuertes, M. B., & Woo, S. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1305-6 · Cited by 54
Cross-Talk between T Cells and Innate Immune Cells Is Crucial for IFN-γ-Dependent Tumor Rejection
Li, Z., Pradera, F., Kammertoens, T., Li, B., Liu, S., & Qin, Z. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.3.1568 · Cited by 40
Landsberg, J., Gaffal, E., Cron, M., Sirokay, J. D., Renn, M., & Tüting, T. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00744.x · Cited by 40
Self-citationTüting, T. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12111 · Cited by 13
Self-citation
Cited by
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
The immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
Metadata
- Authors
- Bald, T., Landsberg, J., Lopez-Ramos, D., Renn, M., Glodde, N., Jansen, P., Gaffal, E., Steitz, J., Tolba, R., Kalinke, U., Limmer, A., Jönsson, G., Hölzel, M., & Tüting, T.
- Venue
- Cancer Discovery
- Published
- 2014-06-01
- Volume
- 4
- Issue
- 6
- Pages
- 674-687
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2147598914
- Cited by
- 256
- References
- 48
- FWCI
- 12.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.